Holders — by stockHoldings — by fund
Commodore Capital LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001831942
$1.68B
disclosed book value
33
positions
13.4%
largest position share
Positions, as of 2026-06-30
top 33 of 33 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | RLAYRELAY THERAPEUTICS INC | 12.0M | $224.5M | 13.4% |
| 2 | ELVNENLIVEN THERAPEUTICS INC | 3.3M | $166.2M | 9.9% |
| 3 | ALKERMES PLC | 3.0M | $157.2M | 9.4% |
| 4 | COGTCOGENT BIOSCIENCES INC | 3.0M | $118.0M | 7% |
| 5 | AMLXAMYLYX PHARMACEUTICALS INC | 5.7M | $101.5M | 6% |
| 6 | DFTXDEFINIUM THERAPEUTICS INC | 2.0M | $94.1M | 5.6% |
| 7 | SYRESPYRE THERAPEUTICS INC | 846,786 | $75.2M | 4.5% |
| 8 | ANROALTO NEUROSCIENCE INC | 2.7M | $71.9M | 4.3% |
| 9 | TNGXTANGO THERAPEUTICS INC | 2.3M | $70.3M | 4.2% |
| 10 | EYPTEYEPOINT INC | 4.6M | $65.8M | 3.9% |
| 11 | TYRATYRA BIOSCIENCES INC | 1.9M | $59.9M | 3.6% |
| 12 | DAMORA THERAPEUTICS INC | 1.9M | $50.4M | 3% |
| 13 | CLDXCELLDEX THERAPEUTICS INC NEW | 1.4M | $50.2M | 3% |
| 14 | PHARVARIS N V | 1.4M | $49.3M | 2.9% |
| 15 | LBRXLB PHARMACEUTICALS INC | 1.5M | $48.7M | 2.9% |
| 16 | ASMBASSEMBLY BIOSCIENCES INC | 1.4M | $38.9M | 2.3% |
| 17 | EDITEDITAS MEDICINE INC | 8.9M | $28.8M | 1.7% |
| 18 | KYMRKYMERA THERAPEUTICS INC | 250,000 | $28.7M | 1.7% |
| 19 | CATXPERSPECTIVE THERAPEUTICS INC | 6.3M | $21.6M | 1.3% |
| 20 | IPSCCENTURY THERAPEUTICS INC | 8.7M | $21.3M | 1.3% |
| 21 | ZURA BIO LTD | 3.3M | $19.2M | 1.1% |
| 22 | AVTXAVALO THERAPEUTICS INC | 1.0M | $18.8M | 1.1% |
| 23 | INFLARX NV | 7.3M | $16.4M | 1% |
| 24 | ANTXAN2 THERAPEUTICS INC | 2.9M | $14.2M | 0.8% |
| 25 | NUVALENT INC | 100,000 | $12.3M | 0.7% |
| 26 | SABSSAB BIOTHERAPEUTICS INC | 2.9M | $11.2M | 0.7% |
| 27 | IKTINHIBIKASE THERAPEUTICS INC | 5.4M | $11.0M | 0.7% |
| 28 | RLMDRELMADA THERAPEUTICS INC | 1.4M | $9.9M | 0.6% |
| 29 | PEPGPEPGEN INC | 4.5M | $8.1M | 0.5% |
| 30 | RESEARCH ALLIANCE CORP III | 500,000 | $5.3M | 0.3% |
| 31 | HELIX ACQUISITION CORP III | 500,000 | $5.3M | 0.3% |
| 32 | LONALEONABIO INC | 464,398 | $4.3M | 0.3% |
| 33 | VTGNVISTAGEN THERAPEUTICS INC | 2.8M | $630,228 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.